Lapiteronel
Lapiteronel (CFG920) is an orally active, nonsteroidal, reversible dual CYP17 and CYP11B2 inhibitor. Lapiteronel has the potential for metastatic castration-resistant prostate cancer research[1][2].
Product Specifications
CAS Number
[1260006-20-9]
Product Name Alternative
CFG920
UNSPSC
12352005
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cfg920.html
Concentration
10mM
Purity
98.51
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N(C2=C(C)C=CN=C2)CCN1C3=CC(Cl)=NC=C3
Molecular Formula
C14H13ClN4O
Molecular Weight
288.73
References & Citations
[1]Chris Lu, et al. Method of treating cancer. WO2021026454A1.|[2]https://patents.google.com/patent/WO2021026454A1/en?oq=WO2021026454
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CYP11; CYP17
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
